This paper provides a sketch of the emerging role of the pharmaceutical salesman, or 'detail man', in the growth years of the American post-World War II pharmaceutical industry. Using training manuals, trade literature, in-house company newsletters, memoirs, and a variety of other published sources, the paper follows the delicate tactics employed by salesmen and their managers in their attempts...

The supply chain represents the critical link between the development of new product and the market in pharmaceutical industry. Over the years, improvements made in supply chain operations have focused largely on ways to reduce cost and gain efficiencies in scale. In addition, powerful regulatory and market forces have provided new incentives for pharmaceutical firms to basically rethink the wa...

Since the adoption of the WTO-TRIPS Agreement in 1994, there has been significant controversy over the impact of pharmaceutical patent protection on the access to medicines in the developing world. In addition to the market exclusivity provided by patents, the pharmaceutical industry has also sought to further extend their monopolies by advocating the need for additional 'regulatory' protection...

Over the last decade, generic penetration in the U.S. pharmaceutical market has increased substantially, providing significant consumer surplus gains. What impact has this rise in generic penetration had on the rate and direction of early stage pharmaceutical innovation? We explore this question using novel data sources and an empirical framework that models the flow of early-stage pharmaceutic...

For nearly 25 years, Iranian Pharmaceutical market has been a closed and centrally controlled one. Although some initiatives have been introduced during the last decade, yet the system is characterized as a closed one and lacks real competition. The current situation of drug in Iran may be characterized as: Intense price control by the Drug Authority i.e. Ministry of Health Ban of d...

Статья посвящена выявлению и систематизации тенденций к изменению маркетинговой деятельности фармацевтической отрасли России, Ð¿Ð¾ÑÐ²Ð¸Ð²ÑˆÐ¸Ñ ÑÑ в связи с усилением ограничений в анализируемые периоды (популяризации ESG...